[Skip to Content]

Upstate Active Clinical Trials

Study Title:

A two-year, phase III randomized, double-blind, parallel-group, placebo-controlled trial to evaluate the safety, efficacy, and tolerability of 300 mg s.c. secukinumab versus placebo, in combination with SoC therapy, in patients with active lupus nephritis. CAIN457Q12301

Upstate Institutional Review Board (IRB) Number:


Study/Protocol ID:


Patient Age Group:


Principal Investigator:

Andras Perl, MD, PhD

Who can I contact for more information?

Name: Joanne M Chilton, CCRP
Phone: 315-464-8240
Email: chiltonj@upstate.edu

Return to Previous Page || Search Again